Emerging Paradigms in Delivery Systems for Antitubercular Therapy

Rajeev Sharma is an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Madhya Pradesh, Gwalior, India. He earned his B.Pharm, M.Pharm, and Ph.D. in Pharmaceutical Sciences from Dr. H. S. Gour Central University, Sagar, India. Dr. Sharma has approximately 13 years of experience in both teaching and industry. He has served as a Junior Research Fellow under AICTE, an ICMR-SRF, and a CSIR-RA Fellow during his research career, and has worked as an Assistant Professor in academia and as a Senior Formulation Development Scientist in the R&D industry. Dr. Sharma has edited two international and two national books and has authored over 30 publications and 21 book chapters in international reference books. His work focuses on recent concepts in immunology, nanobiotechnology, novel drug delivery systems, and targeted and controlled drug delivery of bioactives for the treatment of diseases such as cancer and diabetes. He is a life member of the Association of Pharmaceutical Teachers of India (APTI). Dr. Sharma's work has been cited approximately 1,200 times, and he has an h-index of 17. The cumulative impact factor of his published papers is around 120, according to SCOPUS. He is currently working on a research project funded by the Madhya Pradesh Council of Science and Technology (MPCST). Dr. Sharma has received several awards for his research, including the Young Research Scholar award and various awards for best oral and poster presentations at national and international conferences. His current research interest is in nanocarrier-based targeted approaches for the effective delivery of bioactives.Dr. Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Gwalior. He has over 20 years of teaching and research experience in pharmaceutics, with particular expertise in novel drug delivery systems, localized and targeted drug delivery, and nanocarrier-based therapeutics for disease. His formulations and controlled delivery approaches are aimed at improving therapeutic outcomes. Dr. Mishra has supervised postgraduate and doctoral research scholars, has contributed widely to academic literature through research publications, books, and book chapters with leading international publishers. He has won several awards including Outstanding Scientist Award, and Distinguished Professor Award. He is associated with innovation in pharmaceutical sciences through patented research contributions. Over the course of his career, he has received several academic and scientific recognitions for his contributions to teaching, and research. He has been recognized internationally for his research impact and scholarly contributions.Laxmikant Gautam is a PhD Scholar in the Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India. Professor S.P. Vyas works in the Department of Pharmacy, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India.

• 1. Introduction: An Overview of Novel Approaches for the Treatment of Tuberculosis2. Theragnostic Approaches for the Management of Tuberculosis3. Role of Inorganic Nanoparticles for the Treatment of Tuberculosis4. Role of Polymeric Nanoparticles for the Treatment of Tuberculosis5. Role of Vesicular Carriers for the Treatment of Tuberculosis6. Polymeric Micelles in Therapy of Tuberculosis7. Herbal Approaches for the Treatment of Tuberculosis8. Role of Gut-lung axis in Tuberculosis9. Mucoadhesive Drug Delivery System(s) for the Treatment of Tuberculosis10. Current Gene Therapy Approaches for the Treatment of Tuberculosis11. Novel Targets and Drugs for the Treatment of Tuberculosis12. Targeting Inflammation and Oxidative Stress for the Treatment of Tuberculosis13. Potential Approaches for the Treatment of Drug-resistant Tuberculosis14. Targeted Drug Delivery to the Macrophagic Cellular Tropics in Tuberculosis15. Combination Antitubercular Therapy Using Nanomedicine to Treat and Eradicate Tuberculosis16. Tuberculosis Vaccines: Advancements and Ongoing Clinical Trials17. Future Prospects and Regulatory Aspects for the Management of Tuberculosis